These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 26715391)

  • 1. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
    Hunter SF; Bowen JD; Reder AT
    CNS Drugs; 2016 Feb; 30(2):135-47. PubMed ID: 26715391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod modulates microglial activation to augment markers of remyelination.
    Jackson SJ; Giovannoni G; Baker D
    J Neuroinflammation; 2011 Jul; 8():76. PubMed ID: 21729281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central effects of fingolimod.
    Cruz VT; Fonseca J
    Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.
    Jeffery DR; Rammohan KW; Hawker K; Fox E
    Expert Rev Neurother; 2016; 16(1):31-44. PubMed ID: 26587577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod.
    Fragoso YD; Sato HK
    CNS Neurosci Ther; 2016 Jul; 22(7):633-5. PubMed ID: 27140433
    [No Abstract]   [Full Text] [Related]  

  • 18. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
    Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
    PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.